HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: "Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies".